Intratumoral Influenza Vaccine for Early Colorectal Cancer

Center for Surgical Science, Department of Surgery, Zealand University Hospital0 个研究点目标入组 30 人开始时间: 2020年4月24日最近更新: 2021年10月18日

适应症

试验速览

暂无简介。

•Patients must be mentally capable of understanding the information given.
•Patients must give written informed consent.
•Clinically suspected or histologically verified malignant tumor of the rectum or sigmoid colon.
•Tumor described as passable at index endoscopy.
•Men or women aged at least 18 years.
•Case reviewed by MDT (surgery, radiology, oncology). Case considered curable with standard surgical resection.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 12
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 18

•Highly inflamed gastrointestinal tissue which is ulcerated and bleeding
•Ongoing immunosuppressive treatment.
•Concurrent treatment with an investigational medicinal product.
•Patients with any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study recruitments.
•Advanced tumor stages, clinical UICC stage IV.
•Indication for neoadjuvant chemoradiation or chemotherapy prior to surgery
•Acute surgical resection.
•Any previous allergic reaction to influenza vaccine or constituents, egg and chicken proteins, neomycin, formaldehyde or octoxinol-9
•Acute febrile illness
•Acute infectious disease
•Influenza vaccine administered within 30 days before study inclusion

发起方

Center for Surgical Science, Department of Surgery, Zealand University Hospital